Mazzacco Catherine 4

What Happened Catherine Mazzacco, a member of Sight Sciences’ board of directors, was granted 28,261 restricted stock units (RSUs) on June 4, 2026 under the Issuer’s Non‑Employee Director Compensation Program. The Form 4 reports an acquisition price of $0.00 (standard for RSU grants), and the grant was valued at approximately $130,000 based on the closing price on the grant date. The RSUs vest on the earlier of June 4, 2027 or the Company's 2027 annual meeting, subject to her continued service as a director.

Key Details

• Transaction date: June 4, 2026 (filed June 5, 2026). Transaction code: A (award/grant).
• Grant: 28,261 RSUs; Form 4 shows $0.00 acquisition price, fair value ≈ $130,000 (per footnote).
• Shares/units reported after transaction (per filing): 30,952 shares of Common Stock held of record by the Catherine Mazzacco Irrevocable Trust, plus 28,261 newly granted RSUs and 10,063 previously granted RSUs. That equals 30,952 shares + 38,324 RSUs (69,276 total possible shares if all RSUs vest).
• Holding vehicle: 30,952 shares are held of record by the Catherine Mazzacco Irrevocable Trust (she is a beneficiary).
• No indication of a 10b5-1 plan, cashless exercise, tax‑withholding sale, or late filing in this report.

Context RSUs are contingent awards that convert to common stock if and when they vest; they are common for non‑employee directors and do not represent an immediate purchase or sale. Grants like this are generally routine director compensation rather than an explicit market sentiment signal.